Playlist


Avaza to Host VII Vienna Ball in October as Turkmenistan-Austria Ties Strengthen
13 Apr. 06:52On April 10, 2026, Vienna hosted an expanded meeting of the Austria-Turkmenistan Society, marking the 18th anniversary of the organization and the recent visit of the National Leader of the Turkmen people to Austria. The meeting brought together representatives from major Austrian industrial and medical giants, such as "Waagner Biro Steel and Glass" and the "Gertner Group." This gathering underscored the strategic importance of bilateral relations, with Turkmenistan participating via a high-level online link to discuss future collaborative projects.
A major highlight of the upcoming cooperation is the scheduling of the VII Vienna Ball in Avaza for October 2026. This prestigious cultural event serves as a bridge between the two nations, showcasing the fusion of European traditions with Turkmen hospitality. Additionally, the partnership includes the involvement of Austrian medical firms in the development of the Arkadag city medical cluster and the publication of a special edition of the "Galkynysh" magazine dedicated to the recent diplomatic achievements in Vienna.
The discussions also focused on practical cooperation in sectors such as green energy, digitalization, and the oil and gas industry. Austrian stakeholders reaffirmed their support for Turkmenistan’s global initiatives regarding energy stability and the development of sustainable transport corridors. This session demonstrated that the partnership initiated in 2008 continues to evolve, integrating modern technological solutions and cultural diplomacy into a robust framework for mutual growth.


Simple Vitamin Shows Surprising Results in Pre-Cancerous Blood Conditions, Study Finds
Today in 02:02Daily high-dose supplementation of vitamin C can significantly reduce mortality risks and help prevent severe medical complications in patients with pre-cancerous blood conditions. Researchers from the Van Andel Institute in the United States and Copenhagen University Hospital in Denmark reached this conclusion following a comprehensive three-year follow-up study. The international "EVITA" trial involved volunteers who were administered 1,000 mg of vitamin C daily over the course of a year, while a control group received a placebo.
Although initial hypotheses suggested vitamin C might directly inhibit abnormal cell proliferation, researchers found its primary benefit lay in strengthening the body, reducing systemic inflammation, and lowering rates of anemia, pneumonia, and internal bleeding. Over the three-year observation period, the vitamin C group exhibited a significantly higher survival rate compared to the placebo group. While experts emphasize that these findings remain preliminary and require larger clinical trials before reshaping formal medical treatment protocols, vitamin C continues to show promising potential in supportive patient care.